RVMD Revolution Medicines Inc

$67.75

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 11/17/2025

About Revolution Medicines Inc

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Website: https://www.revmed.com

Sector
LIFE SCIENCES
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1628171
Address
700 SAGINAW DR, REDWOOD CITY, CA, US
Valuation
Market Cap
$6.83B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
3.02
Performance
EPS
$-3.58
Dividend Yield
—
Profit Margin
0.00%
ROE
-29.30%
Technicals
50D MA
$38.30
200D MA
$44.29
52W High
$62.40
52W Low
$29.17
Fundamentals
Shares Outstanding
186M
Target Price
$72.33
Beta
1.37

RVMD EPS Estimates vs Actual

● Estimated
● Actual

RVMD News & Sentiment

Nov 06, 2025 • Zacks Commentary NEUTRAL
Revolution Medicines Posts Wider-Than-Expected Loss in Q3, Sales Nil
RVMD posts a wider Q3 loss as rising R&D and administrative costs weigh, while its RAS(ON) pipeline advances toward key 2026 data.
Nov 06, 2025 • Motley Fool SOMEWHAT-BULLISH
Revolution Medicines ( RVMD ) Earnings Transcript
Image source: The Motley Fool.Wednesday, Nov. 5, 2025 at 4:30 p.m. ETChief Executive Officer - Mark A. GoldsmithContinue reading ...
Nov 04, 2025 • Benzinga NEUTRAL
Revolution Medicines to Participate in November 2025 Investor Conferences - Revolution Medicines ( NASDAQ:RVMD )
REDWOOD CITY, Calif., Nov. 04, 2025 ( GLOBE NEWSWIRE ) -- Revolution Medicines, Inc. ( NASDAQ:RVMD ) , a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A.
Nov 03, 2025 • Benzinga SOMEWHAT-BULLISH
Kailera Therapeutics Appoints Frank Clyburn to Board of Directors
WALTHAM, Mass. and SAN DIEGO, Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Kailera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing a differentiated, late-stage portfolio of next-generation therapies for the treatment of obesity, today announced the appointment of Frank ...
Oct 23, 2025 • Benzinga NEUTRAL
Why Is Tango Therapeutics Stock Falling Today - Tango Therapeutics ( NASDAQ:TNGX )
Tango Therapeutics Inc. ( NASDAQ:TNGX ) revealed data from its ongoing Phase 1/2 study of vopimetostat ( TNG462 ) in patients with MTAP-deleted cancers. As of September 1, 2025, 179 patients were enrolled across all histologies, with 154 at active doses ( 200 mg and above ) .
Oct 23, 2025 • Benzinga NEUTRAL
Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat ( TNG462 ) in Patients with MTAP-deleted Cancers - Tango Therapeutics ( NASDAQ:TNGX )
- 2L MTAP-del pancreatic cancer median progression free survival ( mPFS ) 7.2 months with an objective response rate ( ORR ) of 25% - - Combination studies with RAS ( ON ) inhibitors ongoing, data anticipated 2026 -
Sentiment Snapshot

Average Sentiment Score:

0.083
50 articles with scored sentiment

Overall Sentiment:

Neutral

RVMD Reported Earnings

Aug 06, 2025
Jun 30, 2025 (Pre market)
-0.19 Surprise
  • Reported EPS: $-1.31
  • Estimate: $-1.12
  • Whisper: —
  • Surprise %: -17.0%
May 07, 2025
Mar 31, 2025 (Pre market)
-0.38 Surprise
  • Reported EPS: $-1.13
  • Estimate: $-0.75
  • Whisper: —
  • Surprise %: -50.7%
Feb 26, 2025
Dec 31, 2024 (Post market)
-0.16 Surprise
  • Reported EPS: $-1.12
  • Estimate: $-0.96
  • Whisper: —
  • Surprise %: -16.1%
Nov 06, 2024
Sep 30, 2024 (Post market)
-0.05 Surprise
  • Reported EPS: $-0.94
  • Estimate: $-0.89
  • Whisper: —
  • Surprise %: -5.6%
Aug 07, 2024
Jun 30, 2024 (Post market)
-0.04 Surprise
  • Reported EPS: $-0.81
  • Estimate: $-0.77
  • Whisper: —
  • Surprise %: -5.2%
May 08, 2024
Mar 31, 2024 (Post market)
0.05 Surprise
  • Reported EPS: $-0.70
  • Estimate: $-0.75
  • Whisper: —
  • Surprise %: 6.7%
Feb 26, 2024
Dec 31, 2023 (Post market)
-0.26 Surprise
  • Reported EPS: $-1.14
  • Estimate: $-0.88
  • Whisper: —
  • Surprise %: -29.6%
Nov 06, 2023
Sep 30, 2023 (Post market)
0.02 Surprise
  • Reported EPS: $-0.99
  • Estimate: $-1.01
  • Whisper: —
  • Surprise %: 2.0%
Aug 08, 2023
Jun 30, 2023 (Post market)
-0.1 Surprise
  • Reported EPS: $-0.92
  • Estimate: $-0.82
  • Whisper: —
  • Surprise %: -12.2%

Financials